BRPI0920655A2 - conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos - Google Patents

conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos

Info

Publication number
BRPI0920655A2
BRPI0920655A2 BRPI0920655-8A BRPI0920655A BRPI0920655A2 BR PI0920655 A2 BRPI0920655 A2 BR PI0920655A2 BR PI0920655 A BRPI0920655 A BR PI0920655A BR PI0920655 A2 BRPI0920655 A2 BR PI0920655A2
Authority
BR
Brazil
Prior art keywords
docetaxel
gemcitabine
hpma
conjugates
water
Prior art date
Application number
BRPI0920655-8A
Other languages
English (en)
Inventor
Bok Lee Young
H. Ahn Chang
Joong Kim Deog
Ghandehari Hamidreza
Ray Abhijit
Nan Anjan
Original Assignee
Rexahn Pharmaceuticals, Inc.
University Of Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals, Inc., University Of Maryland filed Critical Rexahn Pharmaceuticals, Inc.
Publication of BRPI0920655A2 publication Critical patent/BRPI0920655A2/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

compostos conjugados de hpma-docetaxel ou gencitabina e uso dos mesmos a presente invenção refere-se a cocomposições solúveis em água de gencitabina e docetaxel formadas conjugando-se a gencitabina ou docetaxel a um polímero solúvel em água tal como n-2-hidroxipropil metacrilamida (hpma). também são descritos métodos de usar as composições da invenção para o tratamento de câncer.
BRPI0920655-8A 2008-10-07 2009-10-07 conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos BRPI0920655A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10339008P 2008-10-07 2008-10-07
US61/103,390 2008-10-07
PCT/US2009/059869 WO2010042638A2 (en) 2008-10-07 2009-10-07 Hpma - docetaxel or gemcitabine conjugates and uses therefore

Publications (1)

Publication Number Publication Date
BRPI0920655A2 true BRPI0920655A2 (pt) 2019-07-09

Family

ID=41683287

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920655-8A BRPI0920655A2 (pt) 2008-10-07 2009-10-07 conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos

Country Status (11)

Country Link
US (1) US9434610B2 (pt)
EP (1) EP2349347A2 (pt)
JP (2) JP2012505228A (pt)
KR (1) KR101705077B1 (pt)
CN (2) CN102264396A (pt)
AU (1) AU2009302387B2 (pt)
BR (1) BRPI0920655A2 (pt)
CA (1) CA2739757C (pt)
IL (1) IL212199A0 (pt)
MX (1) MX2011003738A (pt)
WO (1) WO2010042638A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
EP2210616A1 (en) * 2009-01-21 2010-07-28 Centre National de la Recherche Scientifique Multifunctional stealth nanoparticles for biomedical use
WO2011147330A1 (zh) 2010-05-27 2011-12-01 中国医学科学院药物研究所 双功能共缀物的化学合成及抗肿瘤与抗肿瘤转移作用
US20130217871A1 (en) * 2010-07-09 2013-08-22 Helmut Knoller Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation
JP6420247B2 (ja) 2012-11-13 2018-11-07 ボーイエン セラピューティクス，インコーポレイティド ゲムシタビンプロドラッグ及びその使用
JP6497683B2 (ja) * 2014-09-29 2019-04-10 国立大学法人東北大学 プロテアーゼの基質ペプチド及びプロテアーゼの活性測定方法
EP3258913A1 (en) * 2015-02-17 2017-12-27 Mallinckrodt Nuclear Medicine LLC Modified docetaxel liposome formulations and uses thereof
CN106083960B (zh) 2016-06-15 2019-06-25 常州方圆制药有限公司 新型紫杉类化合物及其制备方法和应用
JPWO2018003739A1 (ja) * 2016-06-30 2019-04-18 レナセラピューティクス株式会社 機能的リガンドを含む核酸複合体
GB2551979A (en) * 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates
CN106581690B (zh) * 2016-12-23 2019-05-28 四川大学 肿瘤微环境刺激可降解的两亲性嵌段hpma聚合物给药系统及其制备方法
CN106880848B (zh) * 2017-02-14 2019-09-06 四川大学 可生物降解的多聚HPMA-Gd磁共振成像探针及其制备方法
CN107550864B (zh) * 2017-08-23 2020-12-18 科笛生物医药(上海)有限公司 Eppt多肽-聚乙二醇-磷脂复合膜材料、其制备方法及主动靶向脂质体递药系统和应用
US12150996B2 (en) 2017-11-17 2024-11-26 Centre National De La Recherche Scientifique Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
CN108359052B (zh) * 2018-04-24 2020-11-17 辽宁大学 一种藤黄酸-叶酸-hpma高分子聚合物及其制备方法和应用
CN116262132B (zh) * 2021-12-13 2024-06-25 中科帅天医药(深圳)有限公司 抗胰腺癌多肽药物偶联物及其无载体自组装纳米药物和制备方法及应用
TR2024014195A1 (tr) * 2024-10-18 2026-04-21 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Anonim Sirketi Anti-kanser ajanin uygulanmasina yöneli̇k poli̇mer bazli taşima si̇stemi̇

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4074039A (en) * 1970-03-26 1978-02-14 Ceskoslovenska Akademie Ved Hydrophilic N,N-diethyl acrylamide copolymers
US3997660A (en) * 1972-02-29 1976-12-14 Ceskoslovenska Akademie Ved Soluble hydrophilic polymers and process for producing the same
CS159937B1 (pt) * 1972-02-29 1975-02-28
CS158458B1 (pt) * 1972-05-02 1974-11-25
CS173846B1 (pt) * 1974-04-23 1977-03-31
CS173849B1 (pt) * 1974-04-25 1977-03-31
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US5965118A (en) * 1997-04-18 1999-10-12 Access Pharmaceuticals, Inc. Polymer-platinum compounds
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6346349B1 (en) * 1999-02-11 2002-02-12 Alcatel Anode invention for lithium/transition metal fluoride molten salt cells and batteries
US20010041189A1 (en) * 1999-04-13 2001-11-15 Jingya Xu Poly(dipeptide) as a drug carrier
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
MXPA02003719A (es) * 1999-10-12 2002-08-30 Cell Therapeutics Inc Fabricacion de congujados de poliglutamato-agente terapeutico.
US7166733B2 (en) * 2000-01-04 2007-01-23 Access Pharmaceuticals, Inc. O,O'-Amidomalonate and N,O-Amidomalonate platinum complexes
CA2396702C (en) * 2000-01-04 2010-03-23 Access Pharmaceuticals, Inc. N,o-amidomalonate platinum complexes
GB0018240D0 (en) * 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
CA2445985A1 (en) * 2001-05-04 2002-11-14 University Of Utah Research Foundation Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
WO2003043568A2 (en) * 2001-11-15 2003-05-30 The Regents Of The University Of California Compositions and methods for the suppression of mammary epithelial cell proliferation
WO2003066068A1 (en) * 2002-02-01 2003-08-14 Intradigm Corporation Hpma-polyamine conjugates and uses therefore
US20050129769A1 (en) * 2002-06-03 2005-06-16 Barry Stephen E. Polymeric articles for carrying therapeutic agents
JP2005535604A (ja) 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
EP1534347B1 (en) * 2002-07-22 2009-12-02 Psimei Pharmaceuticals Plc Conjugates of n-hydroxypropymethacrylamide-methacrylate copolymer with nuclide activation agent and/or anti-cancer compounds
WO2004062588A2 (en) * 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
FR2858936A1 (fr) * 2003-08-22 2005-02-25 Diatos Potentialisation de l'activation de prodrogues de haut poids moleculaire
US20050196343A1 (en) 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US20070287680A1 (en) * 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
CA2572226A1 (en) * 2004-06-28 2006-02-02 Bruce R. Line Radiolabeled nanohybrids targeting solid tumor neovasculature and method of using same
CA2583389A1 (en) 2004-10-07 2006-04-20 Emory University Multifunctional nanoparticles conjugates and their use
US8349991B2 (en) * 2005-04-19 2013-01-08 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
US7647312B2 (en) * 2005-05-12 2010-01-12 Microsoft Corporation System and method for automatic generation of suggested inline search terms
JP5237821B2 (ja) 2005-12-05 2013-07-17 日東電工株式会社 ポリグルタミン酸−アミノ酸結合体および方法
CZ2006592A3 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
US8017141B2 (en) * 2006-12-15 2011-09-13 Advanced Cardiovascular Systems, Inc. Coatings of acrylamide-based copolymers
CN104587484A (zh) * 2009-10-13 2015-05-06 瑞沙恩医药公司 用于抗癌剂递送的聚合物系统

Also Published As

Publication number Publication date
MX2011003738A (es) 2011-09-30
WO2010042638A3 (en) 2010-05-27
JP2012505228A (ja) 2012-03-01
IL212199A0 (en) 2011-06-30
WO2010042638A2 (en) 2010-04-15
CA2739757A1 (en) 2010-04-15
JP2015034170A (ja) 2015-02-19
JP6013424B2 (ja) 2016-10-25
US9434610B2 (en) 2016-09-06
EP2349347A2 (en) 2011-08-03
CN105879044A (zh) 2016-08-24
AU2009302387B2 (en) 2014-12-04
KR101705077B1 (ko) 2017-02-09
CA2739757C (en) 2016-07-05
AU2009302387A1 (en) 2010-04-15
US20100099644A1 (en) 2010-04-22
CN102264396A (zh) 2011-11-30
KR20110076986A (ko) 2011-07-06

Similar Documents

Publication Publication Date Title
WO2010042638A3 (en) Hpma - docetaxel or gemcitabine conjugates and uses therefore
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
BRPI0919447B8 (pt) compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer
CY1120450T1 (el) Διαμορφωτες υποδοχεων οιστρογονων και χρησεις εξ'αυτων
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
MX2010009670A (es) Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CY1121450T1 (el) Θεραπεια συνδυασμου για θεραπεια καρκινου
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
BRPI0905733B8 (pt) composição, formulação farmacêutica, método para a produção de uma composição farmacêutica e uso de uma formulação farmacêutica
CL2012000302A1 (es) Compuestos derivados de tubulisinas; compuestos conjugados que los comprenden; compuestos intermediarios; y uso para tratar el cancer.
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
DOP2009000178A (es) Formulaciones para el tratamiento del cancer
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2599 DE 27/10/2020.